{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:29:02Z","timestamp":1717115342786},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,30]]},"DOI":"10.7759\/cureus.61371","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T15:53:07Z","timestamp":1717084387000},"source":"Crossref","is-referenced-by-count":0,"title":["Positive Myelin Oligodendrocyte Glycoprotein Antibodies in Isolated Optic Neuritis in a 14-Year-Old Child"],"prefix":"10.7759","author":[{"given":"Madhawi J","family":"Albuainain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Alfehaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raafat Hammad Seroor","family":"Jadah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2017.04.004","article-title":"Pediatric optic neuritis","volume":"24","author":"Chang MY","year":"2017","unstructured":"Chang MY, Pineles SL. Pediatric optic neuritis. Semin Pediatr Neurol. 2017, 24:122-8. 10.1016\/j.spen.2017.04.004","journal-title":"Semin Pediatr Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8333-7","article-title":"Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration","volume":"264","author":"Havla J","year":"2017","unstructured":"Havla J, K\u00fcmpfel T, Schinner R, et al.. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol. 2017, 264:139-51. 10.1007\/s00415-016-8333-7","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103222","article-title":"Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease","volume":"56","author":"Akaishi T","year":"2021","unstructured":"Akaishi T, Himori N, Takeshita T, et al.. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease. Mult Scler Relat Disord. 2021, 56:103222. 10.1016\/j.msard.2021.103222","journal-title":"Mult Scler Relat Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan S","year":"2017","unstructured":"Ramanathan S, Mohammad S, Tantsis E, et al.. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2017, 89:127-37. 10.1136\/jnnp-2017-316880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001310","article-title":"Variation in evolving optic neuritis","volume":"41","author":"Bouffard MA","year":"2021","unstructured":"Bouffard MA, Mallery RM, Liao YJ, Torun N. Variation in evolving optic neuritis. J Neuroophthalmol. 2021, 41:476-9. 10.1097\/WNO.0000000000001310","journal-title":"J Neuroophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11920-x","article-title":"An update on optic neuritis","volume":"270","author":"Kraker JA","year":"2023","unstructured":"Kraker JA, Chen JJ. An update on optic neuritis. J Neurol. 2023, 270:5113-26. 10.1007\/s00415-023-11920-x","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56094","article-title":"A comparative review of typical and atypical optic neuritis: advancements in treatments, diagnostics, and prognosis","volume":"16","author":"Spillers NJ","year":"2024","unstructured":"Spillers NJ, Luther PM, Talbot NC, et al.. A comparative review of typical and atypical optic neuritis: advancements in treatments, diagnostics, and prognosis. Cureus. 2024, 16:e56094. 10.7759\/cureus.56094","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.81","article-title":"Optic neuritis","volume":"25","author":"Pau D","year":"2011","unstructured":"Pau D, Al Zubidi N, Yalamanchili S, Plant GT, Lee AG. Optic neuritis. Eye (Lond). 2011, 25:833-42. 10.1038\/eye.2011.81","journal-title":"Eye (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.07.023","article-title":"A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection","volume":"17","author":"Nakamura M","year":"2017","unstructured":"Nakamura M, Iwasaki Y, Takahashi T, et al.. A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection. Mult Scler Relat Disord. 2017, 17:148-50. 10.1016\/j.msard.2017.07.023","journal-title":"Mult Scler Relat Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-018-0561-1","article-title":"Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis","volume":"62","author":"Kezuka T","year":"2018","unstructured":"Kezuka T, Ishikawa H. Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. Jpn J Ophthalmol. 2018, 62:101-8. 10.1007\/s10384-018-0561-1","journal-title":"Jpn J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.53347\/rID-62038","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","author":"Gaillard F","year":"2018","unstructured":"Gaillard F, Sharma R, Alwalid O, et al.. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Radiopaedia.org. 2018, 10.53347\/rID-62038","journal-title":"Radiopaedia.org"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713368","article-title":"Pathogenesis, clinical features, and treatment of patients with myelin oligodendrocyte glycoprotein (MOG) autoantibody-associated disorders focusing on optic neuritis with consideration of autoantibody-binding sites: a review","volume":"24","author":"Tanaka K","year":"2023","unstructured":"Tanaka K, Kezuka T, Ishikawa H, Tanaka M, Sakimura K, Abe M, Kawamura M. Pathogenesis, clinical features, and treatment of patients with myelin oligodendrocyte glycoprotein (MOG) autoantibody-associated disorders focusing on optic neuritis with consideration of autoantibody-binding sites: a review. Int J Mol Sci. 2023, 24:10.3390\/ijms241713368","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody\u00a0disease","volume":"266","author":"Wynford-Thomas R","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody\u00a0disease. J Neurol. 2019, 266:1280-6. 10.1007\/s00415-018-9122-2","journal-title":"J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/genes14122192","article-title":"Uncovering the genetics and physiology behind optic neuritis","volume":"14","author":"Del Negro I","year":"2023","unstructured":"Del Negro I, Pauletto G, Verriello L, Spadea L, Salati C, Ius T, Zeppieri M. Uncovering the genetics and physiology behind optic neuritis. Genes (Basel). 2023, 14:2192. 10.3390\/genes14122192","journal-title":"Genes (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.10.013","article-title":"Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome","volume":"27","author":"Etemadifar M","year":"2019","unstructured":"Etemadifar M, Abbasi M, Salari M, Etemadifar F, Tavakoli H. Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome. Mult Scler Relat Disord. 2019, 27:127-30. 10.1016\/j.msard.2018.10.013","journal-title":"Mult Scler Relat Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurad.2019.06.001","article-title":"MRI features of demyelinating disease associated with anti-MOG antibodies in adults","volume":"46","author":"Den\u00e8ve M","year":"2019","unstructured":"Den\u00e8ve M, Biotti D, Patsoura S, et al.. MRI features of demyelinating disease associated with anti-MOG antibodies in adults. J Neuroradiol. 2019, 46:312-8. 10.1016\/j.neurad.2019.06.001","journal-title":"J Neuroradiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104237","article-title":"Details and outcomes of a large cohort of MOG-IgG associated optic neuritis","volume":"68","author":"Chen JJ","year":"2022","unstructured":"Chen JJ, Flanagan EP, Bhatti MT, et al.. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Mult Scler Relat Disord. 2022, 68:104237. 10.1016\/j.msard.2022.104237","journal-title":"Mult Scler Relat Disord"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002822","article-title":"Pediatric optic neuritis","volume":"87","author":"Yeh EA","year":"2016","unstructured":"Yeh EA, Graves JS, Benson LA, Wassmer E, Waldman A. Pediatric optic neuritis. Neurology. 2016, 87:S53-8. 10.1212\/WNL.0000000000002822","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker BG","year":"1999","unstructured":"Weinshenker BG, O'Brien PC, Petterson TM, et al.. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999, 46:878-86. 10.1002\/1531-8249(199912)46:6&lt;878::aid-ana10&gt;3.0.co;2-q","journal-title":"Ann Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens AL","year":"2020","unstructured":"Bruijstens AL, Wendel EM, Lechner C, et al.. E.U. paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020, 29:41-53. 10.1016\/j.ejpn.2020.10.005","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253353-positive-myelin-oligodendrocyte-glycoprotein-antibodies-in-isolated-optic-neuritis-in-a-14-year-old-child","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T15:53:11Z","timestamp":1717084391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253353-positive-myelin-oligodendrocyte-glycoprotein-antibodies-in-isolated-optic-neuritis-in-a-14-year-old-child"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.61371","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}